Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Head & Neck 1

Conditions

Lymphoma 6Breast Neoplasms 5Lymphoma, Large B-Cell, Diffuse 4Small Cell Lung Carcinoma 3Ovarian Neoplasms 3Lymphoma, Mantle-Cell 3Burkitt Lymphoma 3Waldenstrom Macroglobulinemia 2Triple Negative Breast Neoplasms 2Squamous Cell Carcinoma of Head and Neck 2Prostatic Neoplasms 2Neuroblastoma 2Multiple Myeloma 2Lymphoma, T-Cell 2Lymphoma, Large-Cell, Anaplastic 2Lymphoma, B-Cell, Marginal Zone 2Leukemia, Myeloid, Acute 2Immunoblastic Lymphadenopathy 2Advanced Solid Tumors 2Advanced Malignancies 2Sarcoma 1Primary Myelofibrosis 1Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 1Precursor Cell Lymphoblastic Leukemia-Lymphoma 1Osteosarcoma 1Oligodendroglioma 1Neurofibrosarcoma 1Neuroectodermal Tumors, Primitive, Peripheral 1Mesothelioma 1Lymphoma, T-Cell, Peripheral 1

Interventions

Cisplatin 75Cetuximab 63Radiotherapy 38pembrolizumab 29Radiotherapy, Intensity-Modulated 28Carboplatin 25Fluorouracil 24Docetaxel 24Paclitaxel 19Erlotinib Hydrochloride 13Nivolumab 12Radiation 10Pemetrexed 10durvalumab 8Gemcitabine 8Drug Therapy 8Bevacizumab 7zalutumumab 6Surgical Procedures, Operative 6Panitumumab 6Lapatinib 6Everolimus 6Albumin-Bound Paclitaxel 6130-nm albumin-bound paclitaxel 6epacadostat 5Standard of Care 5Oxaliplatin 5Gefitinib 5Afatinib 5Radiosurgery 4

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Has results × Head and Neck Neoplasms × MLN 8237 × Clear all
NCT04555837 2025-05-20

Alisertib and Pembrolizumab for the Treatment of Patients With Rb-deficient Head and Neck Squamous Cell Cancer

M.D. Anderson Cancer Center

Phase 1/2 Completed
24 enrolled 13 charts
Head & Neck

Squamous Cell Carcinoma of Head and Neck, Head and Neck Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡